Just by considering the laudable accomplishments of the company Clay Siegall leads, one should be able to have a glimpse of the admirable qualities of this noble personality. Clay Siegall doubles as Co-Founder and CEO of Seattle Genetics. Since 1998 when the company came on board, it has been making redoubtable inroads in cancer research. The company has brought massive innovations and advancements in cancer therapy with its stock price tripling within the space of 5 years.
Under the watch of Siegall, Settle Genetics has severally commanded the attention of the world with ground-breaking therapies for cancer patients. For instance, the company was the first to come up with antibody-drug conjugates (ADCs). ADCETRIS® (brentuximab vedotin) was the first of its kind and an invention of Settle Genetics under the leadership of Siegall. Today over 60 countries round the globe are making use of ADCETRIS® in treating cancer patients with amazing testimonies of its effectiveness.
Few individuals can rival Siegall, particularly, in the area of visionary leadership. Many people already know him for his in-depth scientific acumen. The combination of these two amazing qualities has left staff of Seattle Genetics wondering if they can ever have a better leader. He spare-headed the fund-raising of over $1.2 billion for the company. Little wonder Settle Genetics keeps paving the way in innovative technologies necessary for discovering better treatment options for cancer.
Siegall’s commitment and passion towards the complete eradication of cancer leaves people wondering if he will ever show signs of weariness. He seems not to be contented with the 15 patents he currently holds. There are several publications to his credit on new research methods and discoveries. He is currently in the editorial board of three notable scientific journals with over 70 scientific articles in his name.
With such significant contributions to the medical well-being of the human race, it is no surprise catalogue of awards keep coming in and obviously more are on way. University of Maryland where he obtained his PhD in Genetics conferred on him the institution’s award for the Alumnus of the Year for Computer, Math and Natural Science in 2013. A year before then, he was named the Pacific Northwest Ernst & Young Entrepreneur of the Year.
Indeed, Clay Siegall remains a formidable force for wining the war against cancer and other related diseases.